| P50 | author | Julien Zuber | Q42859640 |
| | Denis Glotz | Q56859181 |
| P2093 | author name string | Gary S Hill | |
| | Patrick Bruneval | |
| | Jean-Philippe Empana | |
| | Christophe Legendre | |
| | Dominique Nochy | |
| | Alexandre Loupy | |
| | Dany Anglicheau | |
| | Caroline Suberbielle | |
| | J P Duong van Huyen | |
| P2860 | cites work | Antibody-mediated renal allograft rejection: diagnosis and pathogenesis | Q36759900 |
| | Kidney transplantation: mechanisms of rejection and acceptance | Q37014859 |
| | Relevance of MICA and other non-HLA antibodies in clinical transplantation | Q37233488 |
| | The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells | Q37323152 |
| | Accelerated arteriosclerosis: a form of transplant arteriopathy | Q37629541 |
| | Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study | Q39883589 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Clinicopathological analysis of acute vascular rejection cases after renal transplantation | Q42999230 |
| | Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability | Q45422872 |
| | Anti-HLA class I antibodies transduce signals in endothelial cells resulting in FGF receptor translocation, down-regulation of ICAM-1 and cell proliferation. | Q45984721 |
| | Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. | Q47726666 |
| | Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. | Q47862854 |
| | Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 |
| | Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. | Q51789761 |
| | Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. | Q53860170 |
| | The Banff 97 working classification of renal allograft pathology | Q59314413 |
| | Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha | Q77967475 |
| | Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts | Q79576266 |
| | Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation | Q79741109 |
| | Determinants of poor graft outcome in patients with antibody-mediated acute rejection | Q80054529 |
| | Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels | Q81964906 |
| | Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies | Q84581805 |
| P433 | issue | 5 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 975-983 | |
| P577 | publication date | 2011-04-14 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation | |
| P478 | volume | 22 | |